Comparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic non-small cell lung cancer. A retrospective analysis of the Southern Italy Cooperative Oncology Group trials

Critical Reviews in Oncology/Hematology

Volumn 65, Issue 2, 2008, Pages 164-171

  Comella, P ^a   Gambardella, A ^b   Frasci, G ^a   Avallone, Antonio ^a   Costanzo, R ^a   Gridelli, Cesare ^c   Stupp, Roger ^d   Scagliotti, Giorgio V ^e   Bianco, M ^f   Bilancia, D ^g   Buzzi, F ^h   Bartolucci, R ^h   Cioffi, R ⁱ   Messina, V ⁱ   Carnicelli, P ^j   De Cataldis, G ^j   Del Gaizo, F ^c   Del Prete, S ^k   Di Lullo, L ^l   Farris, A ^m   Putzu, C ^m   Filippelli, G ⁿ   Olivito, V ⁿ   Dima, G ⁿ   Guida, M ^o   Iannelli, A ^p   Condemi, G ^p   Mancarella, S ^q   Maiorino, L ^r   Musico M ^r   Massidda, B ^s   Ionta, M T ^s   Mereu, E ^s   Masullo, P ^t   Muci, D ^q   Paccagnella, A ^u   Panza, N ^v   Palmeri, S ^w   Vaglica, M ^w   Roselli, M ^x   Mariotti, S ^x   Milia, V ^f   Natale, D ^y   Ghiani, M ^z   Barbato, E ^aa   more..

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c S G MOSCATI HOSPITAL   (Italy)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e UNIVERSITY OF TURIN   (Italy)

^f City Hospital   (Italy)

^g SAN CARLO HOSPITAL   (Italy)

^h City Hospital   (Italy)

ⁱ City Hospital   (Italy)

^j Daprocida Hospital   (Italy)

^k City Hospital   (Italy)

^l City Hospital   (Italy)

^m UNIVERSITY OF SASSARI   (Italy)

ⁿ City Hospital   (Italy)

^o NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^p City Hospital   (Italy)

^q City Hospital   (Italy)

^r San Gennaro Hospital   (Italy)

^s UNIVERSITY OF CAGLIARI   (Italy)

^t City Hospital   (Italy)

^u City Hospital   (Italy)

^v CARDARELLI HOSPITAL   (Italy)

^w UNIVERSITY OF PALERMO   (Italy)

^x UNIVERSITY OF ROME TOR VERGATA   (Italy)

^y City Hospital   (Italy)

^z City Hospital   (Italy)

^aa City Hospital   (Italy)

more..

Author keywords

Elderly patients; Gemcitabine; Non small cell lung cancer; Paclitaxel

Indexed keywords

CISPLATIN; GEMCITABINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; AGING; ALOPECIA; ANEMIA; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; ITALY; KIDNEY FUNCTION; LIVER FUNCTION; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 37549005200     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2007.06.014     Document Type: Review

References (41)

1. Frasci G. Chemotherapy of lung cancer in the elderly. Crit Rev Oncol Hematol 41 (2002) 349-361
2. Earle C.C., Tsai J.S., Gelber R.D., Weinstein M.C., Neumann P.J., and Weeks J.C. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol 20 (2001) 1064-1070
3. Bunn Jr. P.A., and Lilenbaum R. Chemotherapy for elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 95 (2003) 341-343
4. Hennessy B.T., Hanrahan E.O., and Breathnach O.S. Chemotherapy options for elderly patients in advanced non-small cell lung cancer. Oncologist 8 (2003) 270-277
5. Yancik R., Ganz P.A., Varricchio C.G., and Conley B. Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base. J Clin Oncol 19 (2001) 1147-1151
6. Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 35 (2000) 181-200
7. Sweeney C.J., Zhu J., Sandler A.B., et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic non-small cell lung carcinoma. Cancer 92 (2001) 2639-2647
8. Soria J.C., Brisgand D., and Le Chevalier T. Do all patients with advanced non-small cell lung cancer benefit from cisplatin-based combination chemotherapy?. Ann Oncol 12 (2001) 1667-1670
9. Billingham L.J., and Cullen M.H. The benefits of chemotherapy in patient subgroups with unresectable non-small cell lung cancer. Ann Oncol 12 (2001) 1671-1675
10. Gridelli C., Aapro M., Ardizzoni A., et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an International Expert Panel. J Clin Oncol 23 (2005) 3125-3137
11. Gridelli C., Ardizzoni A., Le Chevalier T., et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status. 2. Results of an European Experts Panel. Ann Oncol 15 (2004) 419-426
12. Nguyen B., Sandler A., and Denham C. The safety and efficacy of gemcitabine plus cisplatin in the elderly chemo-naive NSCLC patients (age ≥70 years) as compared to those with age <70 years. Proc Am Soc Clin Oncol 18 (1999) 471a [abstr 1818]
13. Kelly K., Giarritta S., Akerley W., et al. Should older patient (pts) receive combination chemotherapy for advanced stage non-small cell lung cancer (NSCLC)? An analysis of Southwest Oncology Trials 9509 and 9308. Proc Am Soc Clin Oncol 20 (2001) 329a [abstr 1313]
14. Langer C.J., Manola J., Bernado P., et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94 (2002) 173-181
15. Lilenbaum R.C., Herndon J., List M., et al. Single-agent (SA) vs combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): a CALGB randomized trial of efficacy, quality of life (QOL), and cost-effectiveness. Proc Am Soc Oncol 21 (2002) 1a [abstr 2]
16. Rocha Lima C.M.S., Herndon J.E., Kosty M., et al. Therapy choices among older patients with lung carcinoma. Cancer 94 (2002) 181-187
17. Langer C.J., Vangel J., Schiller D.P., et al. Age-specific subanalysis of ECOG, 1594: fit elderly patients (70-80 yrs) with NSCLC do as well as younger patients (<70). Proc Am Soc Clin Oncol 22 (2003) 639 [abstr 2571]
18. Belani C.P., and Fossella F.V. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced non-small cell lung carcinoma (TAX 326). Cancer 104 (2005) 2766-2774
19. Perrone F., Gridelli C., and Gallo C. Re: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94 (2002) 62-63
20. The Elderly Lung Cancer Vinorelbine Italian Study Group: Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91 (1999) 66-72
21. Gridelli C., Perrone F., Gallo C., et al. Chemotherapy for elderly patients with advanced non-small cell lung cancer: the Multicenter Italian Lung Cancer in Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95 (2003) 362-372
22. Frasci G., Lorusso V., Panza N., et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J Clin Oncol 18 (2000) 2529-2536
23. Comella P., Frasci G., Carnicelli P., et al. Gemcitabine with either paclitaxel or vinorelbine versus paclitaxel or gemcitabine alone for elderly or unfit advanced non-small cell lung cancer patients. Br J Cancer 91 (2004) 489-497
24. A Southern Italy Cooperative Oncology Group randomised phase II trial, Comella P., Putzu C., Massidda B., et al. Intra-patient alternated dose escalation of paclitaxel and gemcitabine versus paclitaxel followed by fixed dose rate infusion of gemcitabine in fit elderly non-small cell lung cancer patients. Lung Cancer 56 (2007) 263-271
25. Gridelli C., Gallo C., Shepherd F.A., et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21 (2003) 3025-3034
26. Smit E.F., van Meerbeeck J.P.A.M., Lianes P., et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 21 (2003) 3909-3917
27. Comella P., Filippelli G., De Cataldis G., et al. Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101). Ann Oncol 18 (2006) 324-330
28. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
29. Kaplan E.S., and Meier P. Non parametric estimation for incomplete observations. J Am Statist Assoc 53 (1958) 557-580
30. Mantel N. Evaluation of survival data and two new rank of order statistics arising in its considerations. Cancer Chemother Rep 50 (1966) 163-170
31. Cox D.R. Regression models and life tables. J R Statist Assoc 34 (1996) 187-220
32. Pujol J.L., Barlesi F., and Daurès J.P. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Lung Cancer 51 (2006) 335-345
33. D'Addario G., Pintilie M., Leighl N.B., et al. A platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 23 (2005) 2926-2936
34. Pfister D.G., Johnson D.H., Azzoli C.G., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update. J Clin Oncol 22 (2004) 330-353
35. Le Chevalier T., Scagliotti G., Natale R., et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47 (2005) 69-80
36. Cappuzzo F., Novello S., De Marinis F., et al. A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small cell lung cancer patients who are not eligible for platinum-based chemotherapy. Lung Cancer 18 52 (2006) 319-325
37. 2/min (PCI-G) in first-line treatment of adult patients (pts) with advanced non-small cell lung cancer (NSCLC): The GECO study. Proc Am Soc Clin Oncol 24 (2006) 18S [abstr. 7069]
38. Kosmidis P., Mylonakis N., Nicolaides C., et al. Paclitaxel plus Carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 20 (2002) 3578-3585
39. Belani C.P., Dakhil S., Waterhouse D.M., et al. Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer. Ann Oncol 18 (2007) 110-115
40. Extermann M., Aapro M., Bernabei R., et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol/Hematol 55 (2005) 241-252
41. Charlson M.E., Pompei P., Ales K., et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987) 373-383